NewsMarketsBritish Biotech Firm To List on the London Stock...

British Biotech Firm To List on the London Stock Exchange With A Valuation of Over £50m

-

BIOTECH company Oxford Cannabinoid Technologies to float on the London Stock Exchange in a listing which is set to value it at £51.5m

It says it will raise £16.5m from a ‘heavily oversubscribed’ initial public offering and enter the market this Friday.

OCT was founded in 2017 with backing from Kingsley Capital, a London private equity and venture capital business.

Its main research focus is on using cannabinoids to treat pain – a global market worth a potential £7bn a year. 

Buoyant Market For Cannabis

Proceeds of the IPO will be used to prepare its two most advanced drug candidates to begin clinical trials in the third quarter of 2022, reports the Financial Times. 

Neil Mahapatra, OCT co-founder and executive chair, and Managing Partner at Kingsley Capital, told the FT it had been thinking about a ‘private funding round but market conditions appear buoyant for our type of company’.

Existing investors in OCT include UK tobacco company Imperial Brands, which has 16.9% stake and Snoop Dog’s specialist cannabis investment firm Casa Verde with 3.2%. 

OCT’s stated goal is to ‘become a global leader in the development of safe and effective prescription medicines to treat serious and life-threatening human diseases and conditions. 

Its aim is to deliver ‘licensed cannabinoid medicines’ using both natural plant and synthesized cannabinoids.

Severe, Chronic Pain

Its mission statement continues: “OCT’s primary focus is on the drug development for indications in severe, chronic pain conditions, that are one of the biggest challenges facing society today.”

OCT’s role model will be GW Pharmaceuticals which was launched over 20 years ago and has recently been sold to Jazz Pharma for $7.2bn.

In September, last year the Financial Conduct Authority announced it was easing restrictions on cannabis companies floating on the London Stock Exchange.

This has led to three flotations so far this year with MGC Pharmaceuticals making history by being the first on to the LSE followed by Kanabo and Cellular Goods – with all three seeing their stock prices rise sharply

OCT’s  board of directors include Gavin Sathianathan as a non executive director. It was advised by States Bridge Capital, lawyers Penningtons and financial advisors Cairn.

Main image L-R; Neil Mahapatra and Gavin Sathianathan

Peter
Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Akanda Pulls Out Of Lesotho Amid Ongoing Legal Battle, Bruce Linton Joins SynBiotic, & Ananda Completes Acquisition

Akanda The NASDAQ-listed international medical cannabis operator announced last week that it will abandon its operations in Lesotho following...

Concerns Grow As Cannabis Sceptic Appointed To Lead Malta’s Adult-Use Reform

ALMOST one year since passing legislation fears are growing the Maltese Government is set to undermine its commitment to...

Brains Bio Receives NSF’s First CBD Certification For EU GMP CBD API

PRESS RELEASE BRAINS Bioceutical Corp ("Brains Bio" or the "Company"), a global leader in EU GMP grade Cannabidiol (CBD) has...

Amsterdam Cannabis Expo 2022 Latest Scam To Target Industry

AN upcoming European cannabis conference, at which 10,000 cannabis companies were purportedly due to visit, is thought to be...

Juicy Fields Scam May Have Been Small Part Of A Much Larger Criminal Enterprise Says Lawyer As He Prepares To Make Evidence Public

JUICY Fields has already been called the biggest scam in Europe for ‘many, many years’, and its impact on...

Seizure Of 32 Tons Of Cannabis In Spain Was Actually Hemp

BETWEEN telephone calls, Francisco Carbó continues finalising contracts for E-Canna, the hemp processing company he owns based in Valencia,...

Must read

Akanda Pulls Out Of Lesotho Amid Ongoing Legal Battle, Bruce Linton Joins SynBiotic, & Ananda Completes Acquisition

Akanda The NASDAQ-listed international medical cannabis operator announced last...

Concerns Grow As Cannabis Sceptic Appointed To Lead Malta’s Adult-Use Reform

ALMOST one year since passing legislation fears are growing...

You might also likeRELATED
Recommended to you